11.07
14.89%
+1.435
After Hours:
11.01
-0.06
-0.54%
Inovio Pharmaceuticals Inc stock is currently priced at $11.07, with a 24-hour trading volume of 705.42K.
It has seen a +14.89% increased in the last 24 hours and a +3.12% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $9.40 pivot point. If it approaches the $11.26 resistance level, significant changes may occur.
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Inovio Pharmaceuticals Inc (INO) Revenue 2024
INO reported a revenue (TTM) of $832.00 thousand for the quarter ending December 31, 2023, a -91.89% decline year-over-year.
Inovio Pharmaceuticals Inc (INO) Net Income 2024
INO net income (TTM) was -$135.12 million for the quarter ending December 31, 2023, a +51.71% increase year-over-year.
Inovio Pharmaceuticals Inc (INO) Cash Flow 2024
INO recorded a free cash flow (TTM) of -$124.69 million for the quarter ending December 31, 2023, a +42.59% increase year-over-year.
Inovio Pharmaceuticals Inc (INO) Earnings per Share 2024
INO earnings per share (TTM) was -$6.09 for the quarter ending December 31, 2023, a +57.08% growth year-over-year.
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga
Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
Zacks Investment Research
Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript
The Motley Fool
Wall Street Breakfast Podcast: Bitcoin Surges Past $65K; Nikkei Tops 40K
Seeking Alpha
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Cap:
|
Volume (24h):